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Background Increasingattentionhas
been given byresearchers to cannabis use
in individualswith psychosis.Aspsychoses
are relatively low-prevalence disorders,
researchhas beenmostly beenrestricted
to small-scale studies of treatment
samples.The reportedprevalence
estimates obtained fromthese studies
varywidely.
Aims Toprovide prevalence estimates
based on larger samples and to examine
sources of variability inprevalence
estimates across studies.
Method Data from 53 studies of
treatment samples and 5 epidemiological
studieswere analysed.
Results Based ontreatment sample
data, prevalence estimateswere
calculated forcurrentuse (23.0%), current
misuse (11.3%),12-monthuse (29.2%),12-
monthmisuse (18.8%), lifetimeuse (42.1%)
and lifetimemisuse (22.5%).
Epidemiological studies consistently
reportedhighercannabis use andmisuse
prevalence inpeoplewith psychosis.
Conclusions The factormost
consistently associatedwith increased
odds of cannabis prevalencewas
specificityof diagnosis.Factors such as
consumptionpatterns and studydesign
merit furtherconsideration.
Declaration of interest None.
Substance use is widespread in the
community (Costa e Silva, 2002). Cannabis
is the most widely used illegal substance in
Europe (European Monitoring Centre for
Drugs and Drug Addiction, 2001), the
USA (Substance Abuse and Mental Health
Services Administration, 2001) and Australia
(Australian Institute of Health and Welfare,
2002). Studies by Arseneault et al (2002),
van Os et al (2002) and Zammit et al
(2002) have reported an association be-
tween cannabis use and later psychosis.
However, sharp increases in cannabis use
have not been reflected in an increased
prevalence of schizophrenia (Degenhardt
et al, 2003). Also, a notable feature of the
available literature has been the conflicting
findings on the prevalence of substance use
and associated outcomes on psychosis
(Rabinowitz et al, 1998). The conflicting
results have been attributed to factors such
as sample composition (Mueser et al, 1990;
Blanchard et al, 2000), country (Ham-
brecht & Hafner, 1996), recruitment¨
source (Mueser et al, 1990; Hambrecht &
Hafner, 1996; Fowler¨ et al, 1998) and
issues associated with diagnosis and method
of data collection (Mueser et al, 1990;
Hambrecht & Hafner, 1996; Fowler¨ et al,
1998; Blanchard et al, 2000). However,
little research has been undertaken into fac-
tors contributing to the variability in prev-
alence estimates. The aim of our review is
to obtain more reliable estimates of the
prevalence of cannabis use based on larger
samples, to examine factors that may be
associated with variability in prevalence
estimates and to compare prevalence esti-
mates of individuals with and without
psychosis.
METHOD
We examined reports of cannabis use and
misuse prevalence, and whether the varia-
bility in these prevalence estimates was
associated with factors identified by the
researchers as potentially important. These
factors included age and percentage of
males in studies, median year of data collec-
tion, geographic area, recruitment source,
first-episode status, specificity of diagnosis
of psychosis and use of standard diagnostic
classification criteria.
Inclusion criteria
Citations and academic databases were
searched to identify English-language
studies published between 1990 and 2002
which might contain data on the use or mis-
use of cannabis by people diagnosed with
psychosis, schizophrenia-spectrum dis-
orders or schizophrenia. Search terms used
in PsycInfo and Medline were CANNABIS,
MARIHUANA, MARIJUANA or HASH-
ISH combined with SCHIZOPHRENIA,
PSYCHOSIS or PSYCHOTIC. A second
search was conducted using the term DUAL
DIAGNOSIS. Where possible the authors
of studies were contacted to identify
whether specific information on cannabis
and psychosis or schizophrenia was avail-
able. We identified 164 clinical studies that
might have contained information on
cannabis use and psychosis. The following
review is based on 53 studies that met the
inclusion criteria. In addition, five epi-
demiological studies that met the inclusion
criteria were analysed separately.
In-patient and community patient
studies were included if the prevalence of
cannabis use or misuse among patients with
psychosis, schizophrenia-spectrum dis-
orders or schizophrenia could be calculated
(e.g. studies were excluded if there was no
breakdown by diagnosis or it was not clear
whether all patients had psychotic symp-
toms); information was available regarding
the prevalence interval used; substance use
was not an inclusion criterion; the study
did not oversample by age, gender or other
criteria; and patients were only included
once. Research on the same sample was
not included twice for the same prevalence
interval. Where a study reported prevalence
by psychosis in general, as well as by sub-
groups such as schizophrenia, the more
specific information was selected.
For the purpose of this review, misuse
(including dependence) was the focus, since
specific dependence data were not fre-
quently reported. One study (Duke et al,
2001) reporting misuse was included with
the studies reporting use, since ‘misuse’
was defined as ‘any use’. Three time inter-
vals for reporting prevalence of cannabis
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use and misuse were examined. Studies that
reported prevalence in terms of use or mis-
use at a baseline assessment or in a 6-month
period were categorised as current use or
misuse. Studies that reported prevalence in
terms of a 12-month to 18-month period
were categorised as 12-month prevalence
studies, whereas studies reporting any use
or misuse ever were categorised as lifetime
studies.
Analysis
Three sets of analyses were conducted. The
first analysis involved the calculation of
current, 12-month and lifetime prevalence
estimates. For each prevalence interval
(e.g. current use), the total number of re-
ported cannabis users in studies that con-
tained current use data was divided by the
total sample size of the respective studies
to calculate a weighted average.
To examine potential sources of varia-
bility in prevalence estimates, four multi-
variate analyses were performed. The
respective prevalence interval (e.g. lifetime
misuse) was the dependent variable and
the following variables were entered as
independent variables: recruitment source
(whether study participants were recruited
from a hospital, community setting or a
combination of both); geographic area
(studies were grouped as being conducted
in either Australasia, continental Europe,
North America or the UK); use of standard-
ised substance misuse classification criteria
(criteria reflecting an ICD or DSM diag-
nosis, as opposed to criteria devised by
study authors); specificity of the diagnosis
of psychosis (psychosis, schizophrenia-
spectrum disorders or schizophrenia only)
and first-episode status (a specific first-
episode sample or not). Average age of the
study samples, percentage of males in a
study and the median year of data
collection for each study were covariates.
Missing values for average age and percen-
tage of males resulted in some studies not
being included in the multivariate analyses
(Table 1). Multinomial logistic regression,
which can be used to analyse dichotomous
variables, was selected in preference to
logistic regression for the analyses, because
it has the advantage of calculating the
likelihood ratio test for each individual
independent variable (Menard, 2001). The
likelihood ratio test is useful for determin-
ing the significance of variables included
in a logistic regression model. The odds
ratios reported in Tables 4 and 5 refer to
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Table1 Studies included in the analyses of clinical data
Study Prevalence data Study distinguished between
misuse and dependence
Arndt et al (1992) Lifetime misuse No
Bersani et al (2002) Lifetime misuse, lifetime use No
Brewer et al (2001) Current use No
Cantor-Graae et al (2001) Lifetime misuse No
Cantwell et al (1999) 12-month misuse No
Carr et al (2002) Lifetime misuse, 12-month use No
Chouljian et al (1995) Current misuse No
Claassen et al (1997) Urine test No
Condren et al (2001) Lifetime misuse No
DeQuardo et al (1994) Lifetime misuse No
Dervaux et al (2001) Lifetime misuse No
Diwan et al (1998) Current use, lifetime use No
Dixon et al (1991) Lifetime misuse No
Duke et al (2001) Current use, lifetime use No
Fowler et al (1998) Current use andmisuse, urine test, lifetime
use andmisuse
Yes
Gearon et al (2001) Lifetime misuse No
Graham et al (2001) 12-month use andmisuse Yes
Gut-Fayand et al (2001) Lifetime misuse Yes
Hambrecht & Hafner (1996)« Lifetime misuse No
Jablensky et al (2000) Lifetime use andmisuse No
Kamali et al (2000) Current misuse, lifetime misuse No
King et al (1994)1 Urine test, lifetime use No
Kirkpatrick et al (1996) Current use andmisuse, lifetime use and
misuse
No
Kovasznay et al (1997) Current use No
Krausz et al (1996)1 Lifetime use andmisuse No
Ley et al (2002) Urine test No
Martinez-Arevalo et al (1994) Current use, lifetime use No
Mathers et al (1991)1 Urine test, lifetime use No
McCreadie (2002) Lifetimemisuse, 12-month use andmisuse No
McGuire et al (1994) Urine test No
Menezes et al (1996) Lifetime use, 12-month use andmisuse No
Modestin et al (1997)1 Current use, urine test No
Mueser et al (1990) Current and lifetimemisuse No
Mueser et al (1992) Lifetime misuse No
Mueser et al (2000) Lifetime misuse No
Negrete & Gill (1999) Current use andmisuse No
Nu•ez & Gurpegui (2002)¤ Urine test No
Peralta & Cuesta (1992) 12-month misuse No
Rabinowitz et al (1998) Lifetime misuse No
Sembhi & Lee (1999) Current and lifetime use, urine test No
Sevy et al (2001) Lifetime misuse Yes
Shaner et al (1993) Current misuse No
Shumway et al (1994) 12-month use No
Sokolski et al (1994) Lifetime misuse No
Soyka et al (1993) Current and lifetimemisuse No
Steadman et al (1998) Current and lifetime use No
Veen et al (2002) Current and lifetime use, 12-monthmisuse No
Verdoux et al (1999) Current use, lifetime misuse, urine test No
Warner et al (1994) Current and lifetime use No
Wolford et al (1999) Urine test No
Wright et al (2001) Currentmisuse, lifetime and12-month use No
Zaretsky et al (1993)1 Current use No
Ziedonis & Trudeau (1997) Current misuse No
1. Study excluded frommultivariate analysis because of missing data on age or gender.
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the respective increase or decrease in the
odds of cannabis use or misuse associated
with each independent variable.
The third analysis compared prevalence
estimates among individuals with and with-
out psychosis in community population
studies. Uncorrected odds ratios were cal-
culated for epidemiological studies using
data provided by the respective study
authors. All analyses were performed using
the Statistical Package for the Social
Sciences, version 10.
RESULTS
Cannabis use and misuse
prevalence estimates from
treatment samples
Tables 2 and 3 display prevalences of cur-
rent, 12-month and lifetime cannabis use
and misuse, respectively. Few studies have
examined use and misuse in the same study.
The average percentage of people using
cannabis whose use was classified as ‘mis-
use’ was 42.9% for current use, 44.7%
for 12-month use and 53.5% for lifetime
use. Most studies reporting the prevalence
of cannabis misuse did not distinguish
between misuse and dependence (see
Table 1). Of the four studies that provided
data on misuse and dependence, three
reported that over 75% of those with
cannabis misuse met the criteria for misuse,
rather than dependence. In contrast, the
fourth study reported that 78.6% of
patients with lifetime use and 68.0% of
those with current use were diagnosed with
dependence rather than misuse. The age
and gender compositions of this latter study
and the other community-based study with
misuse–dependence data were similar.
However, the study diagnoses were
based, respectively, on data collected by a
trained research assistant who administered
the structured clinical interview for
DSM–III–R, and on ratings made by key-
workers on scales based on DSM–IV
criteria.
Studies that used criteria from a stand-
ardised classification system reported a
prevalence of 22.1% for lifetime misuse
and 19.1% for 12-month misuse. The re-
spective prevalence rates for lifetime misuse
and 12-month misuse reported by the
studies that did not use criteria from a
standardised classification system were
25.4% and 17.7%. All studies reporting
current misuse had used criteria from a
standardised classification system (e.g.
DSM or ICD) to make this diagnosis.
Prevalence estimates obtained
from urine testing of treatment
samples
The prevalence of cannabis use detected by
urine testing was 12.3% (s.e.m.¼0.9). This
was based on a sample of 1460 pooled from
12 studies. Information on the cut-off
criteria used to determine the presence of
cannabinoids in urine was reported in only
seven of the available studies. Criteria
ranged from 20 ng/ml to 100 ng/ml. The
respective percentages of positive urine tests
were 12.0% at 20 ng/ml (three studies),
31.4% at 35 ng/ml (one study), 14.6% at
3 0 8
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Table 2 Prevalence of cannabis use as a weighted average
Prevalence interval Number of studies
(sample size)
Weighted average
% (s.e.m.)
Prevalence range
of studies
%
Current 14 (n¼1695) 23.1 (1.0) 4.5^81.1
12-month 6 (n¼1064) 29.2 (1.4) 10.0^45.8
Lifetime 15 (n¼3119) 42.2 (0.9) 19.2^89.1
Table 3 Prevalence of cannabis misuse as a weighted average
Prevalence interval Number of studies
(sample size)
Weighted average
% (s.e.m.)
Prevalence range
of studies
%
Current 11 (n¼2173) 11.3 (0.7) 1.9^20.8
12-month 6 (n¼1102) 18.7 (1.2) 3.5^32.4
Lifetime 26 (n¼4553) 22.5 (0.6) 5.5^54.9
Table 4 Multinomial logistic regression of variables associatedwith cannabis use
Variables Current use (n¼1500) Lifetime use (n¼2435)
Odds ratio (95% CI) P Odds ratio (95% CI) P
Average age of sample 0.88 (0.80^0.96) 0.004 0.94 (0.91^0.96) 50.001
Percentage of males 1.06 (1.03^1.09) 50.001 1.04 (1.03^1.05) 50.001
Geographic area
Australasia 1.56 (0.06^38.04) NS 1.70 (1.38^2.10) 50.001
Europe (continental) 0.78 (0.05^11.80) NS 0.91 (0.58^1.43) NS
North America 1.25 (0.08^18.71) NS 1.53 (1.14^2.05) 0.004
UK1 1.00
Median year data collected 1.05 (0.97^1.14) NS 0.78 (0.75^0.81) 50.001
Specificity of diagnosis
Psychosis 5.49 (2.98^10.11) 50.001 5.17 (4.22^6.33) 50.001
Schizophrenia spectrum 2.40 (1.05^5.47) 0.038 1.58 (1.24^2.02) 50.001
Schizophrenia1 1.00
Recruitment source
Mixed 3.90 (1.25^12.15) 0.019 0.23 (0.17^0.31) 50.001
Community 1.44 (0.75^2.76) NS 0.56 (0.43^0.74) 50.001
Hospital1 1.00
First episode status
Not first episode 1.68 (1.03^2.74) 0.038 0.11 (0.08^0.15) 50.001
First episode1 1.00
1. Reference category.
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50 ng/ml (one study) and 10.0% at 100 ng/
ml (two studies).
Multivariate analysis
The results of the multinomial logistic
regression are reported in Tables 4 and 5.
Variables were initially entered in the
following order: recruitment source, geo-
graphic area, use of standardised substance
misuse classification criteria, specificity of
diagnosis of psychosis, and first-episode
status. Average age of the study samples,
percentage of males in a study and the med-
ian year of data collection for each study
were covariates. The largest odds were con-
sistently associated with a broader diag-
nosis of psychosis (e.g. psychosis or
schizophrenia-spectrum disorder compared
with schizophrenia). The significance levels
obtained for each of the four models indi-
cated that the independent variables signif-
icantly contributed to each model, but they
were weak predictors as indicated by the
resulting McFadden statistics (ranged from
0.019 to 0.155) which are analogues of R2
(Menard, 2001). Each analysis obtained a
statistically significant model chi-square.
Cannabis use andmisuse
prevalence in epidemiological
studies
Table 6 lists the prevalence estimates
obtained from epidemiological studies. All
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Table 5 Multinomial logistic regression of variables associatedwith cannabis misuse
Variables Currentmisuse (n¼2173) Lifetimemisuse (n¼4078)
Odds
ratio
(95% CI) P Odds
ratio
(95% CI) P
Average age of sample 1.11 (1.06^1.17) 50.001 1.01 (0.97^1.06) NS
Percentage of males 1.03 (1.01^1.06) 0.015 1.02 (1.01^1.04) 0.004
Geographic area
Australasia 1.53 (0.52^4.49) NS 2.13 (1.44^3.17) 50.001
Europe (continental) 0.09 (0.03^0.27) 50.001 1.00 (0.49^2.04) NS
North America 0.22 (0.08^0.58) 0.002 1.84 (0.95^3.54) NS
UK1 1.00 1.00
Median year data collected 0.93 (0.84^1.03) NS 1.04 (1.01^1.08) 0.028
Criteria of misuse
Non-standardised criteria 1.54 (1.11^2.14) 0.009
Standardised criteria1 2 1.00
Specificity of diagnosis
Psychosis 1.53 (0.76^3.09) NS
Schizophrenia spectrum 10.43 (2.93^37.06) 50.001 1.90 (1.27^2.84) 0.002
Schizophrenia1 1.00 1.00
Recruitment source
Mixed 0.51 (0.22^1.17) NS 0.68 (0.49^0.95) 0.023
Community 2 1.48 (0.79^2.75) NS
Hospital1 1.00 1.00
First episode status
Not first episode 1.47 (0.85^2.54) NS
First episode1 2 1.00
1. Reference category.
2. No study available for comparison.
Table 6 Prevalence of cannabis use andmisuse estimates from epidemiological studies
Study sample Non-psychosis
group
Psychosis
group
Odds ratio (95% CI)
Preva-
lence
(%)
Total
sample
size
(n)
Preva-
lence
(%)
Total
sample
size
(n)
Lifetime use
Coulthard et al (2002) UK household sample (aged 16^74 years) 21.9 8484 34.5 58 1.88 (1.09^3.24)
van Os et al (2002) Dutch household sample (aged 18^64 years) 9.4 6968 18.7 107 2.21 (1.35^3.61)
Zammit et al (2002) Swedish conscripts (cohort aged18^20years atbaseline:
20-year follow-up)
11.0 47 703 17.7 779 1.74 (1.45^2.10)
12-month use
Arseneault et al (2002) NewZealand birth cohort (aged 26 years) 50.6 934 69.4 36 2.22 (1.08^4.55)
Coulthard et al (2002) UK household sample (aged 16^74 years) 8.0 8484 12.1 58 1.58 (0.71^3.48)1
Degenhardt & Hall (2001) Australian household sample (aged 18^50 years) 10.5 6623 31.3 99 3.98 (2.59^6.14)
12-monthmisuse
Arseneault et al (2002) NewZealand birth cohort (aged 26 years) 8.6 934 27.8 36 4.11 (1.91^8.82)
Coulthard et al (2002) UK household sample (aged 16^74 years) 2.5 8484 6.9 58 2.92 (1.05^8.13)2
Degenhardt & Hall (2001) Australian household sample (aged 18^50 years) 3.3 6623 16.2 99 5.86 (3.37^10.18)
1. Not statistically significant.
2. Statistically significant when cut-off was on symptom of dependence.Odds ratio was not statistically significant when the cut-off was two dependence symptoms.
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the studies showed higher odds of cannabis
use or misuse for people with psychosis.
The lifetime use estimates (van Os et al,
2002; Zammit et al, 2002) were lower than
the lifetime use estimates in any study
reported in Table 2. The 12-month
prevalence use and misuse estimates for
the psychosis group in the Degenhardt &
Hall (2001) study are comparable to the
estimates in Tables 2 and 3.
The standard reference on cannabis
misuse prevalence in the community among
people with schizophrenia is the Epidemio-
logic Catchment Area study (Regier et al,
1990). The unweighted prevalence of a life-
time DSM–III cannabis misuse diagnosis
among people with schizophrenia in this
latter study was 19.7%, 13.4% in the
household sample and a 36.2% prevalence
in the institutional sample (D. Rae,
personal communication, 2002).
DISCUSSION
A systematic review of published studies
found that the prevalence of misuse of can-
nabis was approximately half that of its
use, and that 12-month misuse prevalence
provided a sound indication of lifetime mis-
use prevalence. Current misuse prevalence
displayed the least variation across studies.
These estimates provide a benchmark to
evaluate prevalence reported in subsequent
research, as well as to assist with decisions
regarding the selection of appropriate pre-
valence intervals. The prevalence estimates
were based on a total sample that was
larger than has previously been reported.
Study recruitment source
We found no consistent pattern of in-
creased or decreased odds associated with
recruitment source, although analysis of
epidemiological data indicated a consistent
pattern of increased odds of cannabis use
and misuse associated with psychosis. De-
spite different study designs, the prevalence
estimates obtained for people with psycho-
sis from the epidemiological studies were
consistently higher than the estimates for
non-psychosis samples. Although the low
lifetime prevalence use in the Swedish birth
cohort study (Zammit et al, 2002) could be
attributed to the fact that the data were col-
lected in 1969–70, the prevalence estimate
was similar to the Dutch household study
(van Os et al, 2002) which collected data
in 1996. The lifetime prevalence in the lat-
ter study was almost half the current use
prevalence reported in a population-based
first-incidence Dutch psychosis study (Veen
et al, 2002). Given that cannabis is readily
available in The Netherlands, the low life-
time prevalence reported in the epidemio-
logical study supports the hypothesis that
prevalence estimates may be inflated in
clinical samples. In contrast, the Australian
household study (Degenhardt & Hall,
2001) obtained 12-month prevalence esti-
mates similar to those reported in Tables
2 and 3.
Epidemiological studies have important
advantages over clinical samples in relation
to sample size and representativeness; how-
ever, with the exception of the Swedish
birth cohort study (Zammit et al, 2002),
the number of people in the epidemiologi-
cal studies with psychosis was relatively
small. Additionally, across the studies there
was variation in the methods used and clin-
ical experience of the researchers employed
to identify individuals with psychosis.
In relation to treatment samples, only
two studies provided prevalence estimates
for samples from different sources (Soyka
et al, 1993; Carr et al, 2002). In the earlier
study differences in the prevalence esti-
mates might be accounted for by differ-
ences in admission criteria and functions
of the hospitals, and the fact that the uni-
versity sample had a significantly lower
percentage of males – indeed, the lowest
percentage of males of any study reviewed.
Diagnostic criteria and data
collection
The most consistent finding across the mul-
tivariate analyses was the increased odds
associated with a broader diagnosis (e.g.
psychosis compared with schizophrenia).
This suggests that a fundamental criterion
for inclusion in a study might account for
some of the variation in prevalence esti-
mates. One explanation for the increased
odds associated with the broader diagnosis
of psychosis is the possible inclusion of
individuals with drug-induced psychoses.
The criteria for diagnosing substance
misuse could only be examined for lifetime
misuse, as all studies of current misuse had
adopted some form of standardised criteria.
It was originally intended to examine pre-
valence in terms of the method used to
diagnose substance misuse; however, the
diversity of approaches in reviewed studies
(e.g. the use of some questions from struc-
tured interviews within clinical interviews)
made categorising studies using this
criterion problematic.
Differences in prevalence have been
accounted for by both criteria and infor-
mation variance (Klerman, 1985). The
importance of considering the criteria
used comes from a study that compared
substance use diagnoses in a first-episode
patient sample made by a research team
with those made by clinicians. The research
team and clinicians diagnosed cannabis use
disorder in 8.5% and 33.3% of the patients
respectively. Generally, disagreement was
attributed to differences in applying diag-
nostic criteria rather than differences in
the information that was available (Fennig
et al, 1996). In contrast, the differences in
prevalence estimates reported in the Epi-
demiologic Catchment Area and National
Comorbidity Survey studies have been
attributed to information variance (Regier
et al, 1998; Narrow et al, 2002). This infor-
mation variance was considered to be due
to differences in the nature of interviews
that were employed.
Study design has also been reported to
affect disclosure of sensitive information
(Kessler et al, 2000). Inconsistencies in
reporting have been found to be greater
among people using cocaine compared with
those using cannabis, with inconsistent
accounts of lifetime use more likely by
people with lower levels of use (Fendrich
& Mackesy Amiti, 1995). Although the
presence of underreporting can be difficult
to determine, patient self-report has been
found to accord with urine tests (Fowler
et al, 1998) and collateral sources (Carey
& Simons, 2000). However, a study by
Swartz et al (2003) found that cannabis
prevalence differed according to the meth-
od of data collection: self-report 9.4%,
urine testing 6.4% and hair analysis
19.9%. The prevalence obtained by hair
analysis is closest to the current use
reported in Table 2.
Prevalence estimates obtained by urine
testing raise two issues of interest. First,
prevalence was not markedly lower when
a higher cut-off criterion was used. Second,
some studies noted that patients who re-
ported cannabis use did not return a posi-
tive result (Condren et al, 2001). A similar
finding has been reported in relation to hair
analysis (Selten et al, 2002). A factor
accounting for the former finding and dif-
ferences in prevalence is likely to be the
frequency of cannabis use and the time in-
terval from use to testing. At the 20 ng/ml
cut-off level, infrequent cannabis users
310
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would on average be expected to test posi-
tive 2–3 days after cannabis use, whereas
frequent users would on average test
positive for 9–12 days (Kelly & Jones,
1992). Information on when testing was
conducted (e.g. average days after
admission), method of testing and cut-off
criteria employed are necessary to evaluate
more fully cannabis prevalence data based
on urine testing.
Age and gender
Age was associated with slightly increased
odds of misuse (current and lifetime) and
decreased odds of use (current and life-
time); higher percentages of males in a
study sample were associated with a small
increase in odds of use and misuse across
the prevalence intervals. Although two
studies were identified that did not find dif-
ferences in either age or gender between
those using cannabis and other patients
(Peralta & Cuesta, 1992; Sembhi & Lee,
1999), a number of studies have found
that cannabis use and misuse are associated
with younger age (Mueser et al, 1990,
2000; Mathers et al, 1991; Bersani et al,
2002; Veen et al, 2002) and being male
(Mueser et al, 1990, 1992, 2000; Mathers
et al, 1991; Negrete & Gill, 1999; Nunez´ ˜
& Gurpegui, 2002; Veen et al, 2002). The
findings from our review also suggest that
the age and gender composition of study
samples would be expected to contribute
to variation in prevalence estimates across
studies.
Year of data collection
No consistent association was found be-
tween prevalence and median year of data
collection. A review by Cuffel (1992)
reported an association between the year
of data collection and alcohol or ampheta-
mine use; in that review, more recent
studies reported higher prevalence. The
studies included by Cuffel were from the
period 1960–1991 and there were in-
sufficient studies on cannabis to examine
this relationship. Our review included
studies published between 1990 and 2002,
which collected data between 1983 and
2002. It may be the case that more time is
required to determine a temporal pattern,
or that other factors may interact with time
period, such as changes in cannabis
availability.
An illustration of how prevalence esti-
mates vary over time is illustrated by two
US studies. The first study, which collected
data between 1983 and 1986 (Mueser et al,
1990), reported a 40% lifetime prevalence
of cannabis use. A subsequent study from
the same area (Mueser et al, 1992) that
collected data between 1986 and 1990
reported a lifetime prevalence of 15.7%.
These findings need to be considered in
the context of the decreasing use of canna-
bis reported in the USA in the 1980s and
the increased use of cocaine in the same
period (Costa e Silva, 2002).
Geographic area
No consistent association was found be-
tween prevalence of use or misuse and geo-
graphic area. Where prevalence estimates
vary by geographic area this may be due
to factors such as drug availability or
changing trends in drug preference, as
well as preferences for different research
designs.
Limitations of our study
A limitation of our review is that studies of
varying methodologies and methodological
rigour were combined. The impact of dif-
ferent methods on prevalence estimates is
difficult to determine and requires further
attention; the issue of study quality was
addressed by only including studies that
met the inclusion criteria, especially the re-
quirement that adequate detail was avail-
able. Pooling studies from different
countries and time periods may have been
problematic; however, these variables were
included in the logistic regression and speci-
fic prevalence estimates for these variables
were provided separately.
Future research
This review produced cannabis prevalence
estimates based on the most comprehensive
data to date and systematically examined
factors that might account for the variation
in prevalence estimates across studies. The
increased odds of cannabis use and misuse
among the population-based studies sup-
ports the view that the high prevalence
rates in treatment samples are not simply
a sampling artefact. Among the treatment
samples, specificity of the diagnosis of psy-
chosis was the variable most consistently
associated with increased odds of cannabis
use or misuse. The percentage of male par-
ticipants in the study samples was asso-
ciated with a small increase in odds of use
and misuse, whereas age was associated
with increased odds of misuse and
decreased odds of use. This was the one
consistent difference between the use and
misuse models. As the majority of variance
in predicting use and misuse was not ac-
counted for by the common methodological
variables included in this review, a more
finely grained examination of the impact
of different data collection tools is required.
It will be important to examine additional
factors such as motivation, disorder sever-
ity, craving and consumption levels, which
might account for continued cannabis use
and misuse. Such research has both clinical
and policy implications, particularly in
countries with high prevalence estimates.
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CLINICAL IMPLICATIONS
& The high prevalence of cannabis use andmisuse among peoplewith psychosis does
not appear to be an artefact of sampling.
& Least variability in prevalence estimates was foundwhen currentmisusewas
diagnosed using a standardised assessment approach.
& For urine testing to be an effectivemeans of determining current use, issues such
as the interval between use and testing, cut-off levels andmethod need to be
considered.
LIMITATIONS
& Studies of varyingmethodologies andmethodological rigour were combined.
& Pooling studies from different countries and time periodsmay be problematic.
& Amore fine-grained approach to examining how data collection differed across
studies was not undertaken.
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